ClinicalTrials.gg
CompletedNCT07717814Updated Jul 21, 2026

A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity

A Phase 1 interventional study of AMG 133 (frozen liquid) and AMG 133 (liquid) in Overweight and Obesity, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.
  • Registered 1 year 7 months after the study started (first participant enrolled Nov 2024, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Enrollment
20th of 28
154 · median 275
Started
2024
with 4 others
Phase 1
14 of 28
3 open now
Registered
23rd of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 20th largest by enrollment, is one of 5 that started in 2024, is one of 14 in phase 1, and was the 23rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered as a single subcutaneous (SC) dose using a liquid drug product in vial compared to a frozen liquid drug product in vial in participants living with overweight or obesity.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

Keywords

  • Obesity
  • AMG 133
  • Maridebart cafraglutide
  • MariTide
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 154 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide signed and dated before any study procedures.
  2. Be male or female, 18 to 65 years old, at screening.
  3. May have well-controlled conditions such as obstructive sleep apnea, high blood pressure, high cholesterol, or hypothyroidism on stable treatment for ≥ 3 months. Other mild, stable health conditions may be allowed with investigator and medical monitor approval.
  4. (BMI) between 25 and 40 kg/m² at screening.
  5. Stable body weight (less than 5 kg change by self-report) during the 3 months before screening.
  6. No major changes in diet or lifestyle (such as new weight-loss or exercise programs) during the past 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Any significant medical condition or abnormal test result that could increase risk or interfere with study participation, based on investigator judgment.
  2. Diabetes (any type except past gestational diabetes) or (HbA1c) ≥ 6.5%.
  3. Endocrine disorders that can cause obesity (for example, Cushing's syndrome).
  4. Pancreatitis within the past year, or abnormal pancreatic blood tests (lipase/amylase > 2 × normal) or fasting triglycerides > 500 mg/dL.
  5. Cancer within 5 years (except treated non-melanoma skin cancer or in-situ cervical/breast lesions).
  6. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  7. Uncontrolled thyroid disease (thyroid stimulating hormone [TSH] > 6.0 or \< 0.4 mIU/L). Participants on stable thyroid-replacement therapy for ≥ 3 months may be included if TSH is in range.
  8. History or current signs of gastroparesis (delayed stomach emptying).
  9. Weight-loss surgery within 6 months before check-in.
  10. Heart or blood-vessel disease (aside from controlled high blood pressure or cholesterol), such as heart attack, angina, valve disease, or prior bypass/stent.
  11. abnormal heart rhythm on (ECG) at screening or check-in.
  12. corrected for heart rate using Fridericia's method (QTcF) > 450 ms (males) or > 470 ms (females), or a history of long QT syndrome.
  13. Second- or third-degree heart block.
  14. Blood pressure > 150/95 mmHg or \< 90/50 mmHg, or pulse > 110 bpm. A single repeat is allowed if values normalize.
  15. Allergy or to AMG 133 or its ingredients.
  16. Poor veins for blood draws.
  17. Kidney function (estimated [eGFR]) ≤ 60 mL/min/1.73 m\^2.
  18. Liver enzymes ( [ALT] or aspartate aminotransferase [AST]) > 2X normal.
  19. Positive test for , , or (HIV) (exceptions apply for prior vaccination or resolved hepatitis B virus [HBV] infection).
  20. Current or recent (within 6 months) suicidal thoughts, suicide attempts, or major psychiatric illness, including depression.
  21. Use of any prescription or over-the-counter medicines within 30 days or 5 half-lives (whichever is longer) before check-in, except:

    • Acetaminophen ≤ 2 g/day for pain
    • Hormone replacement (e.g., estrogen, thyroid) or hormonal
    • Stable treatments (≥ 3 months) for high blood pressure, high cholesterol, or other mild, well-controlled conditions approved by the investigator and medical monitor.
  22. Use of any glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptor agonist/antagonist within 3 months.
  23. Use of herbal medicines, vitamins, or supplements within 30 days, unless approved by the investigator and sponsor.
  24. Consumption of poppy-seed-containing foods within 7 days before check-in.
  25. Alcohol abuse or regular intake > 21 units/week (men) or > 14 units/week (women), or drug abuse within 1 year. (1 unit = 12 oz beer, 1.5 oz liquor, 5 oz wine.)
  26. Alcohol use within 48 hours before check-in, or unwillingness to limit alcohol to ≤ 1 unit/day from discharge through study end.
  27. Strenuous exercise or a new exercise program within 7 days before check-in.
  28. Positive drug screen or tetrahydrocannabinol (THC) test, or unwillingness to avoid illicit drugs/THC through end of study.
  29. Positive pregnancy test at screening or check-in.
  30. Breastfeeding, or planning to breastfeed within 16 weeks after receiving AMG 133.
  31. Men and women unwilling to use required contraception through 16 weeks after receiving AMG 133.
  32. Men unwilling to abstain from sperm donation or women unwilling to abstain from egg donation through 16 weeks after receiving AMG 133.
  33. Men with female partners of unwilling to inform their partner and adhere to contraception requirements.
  34. Men with pregnant partners (or partners planning pregnancy) unwilling to use effective contraception or abstain from intercourse through 16 weeks after receiving AMG 133.
  35. Participation in another drug study within 30 days or 5 half-lives (whichever is longer).
  36. Previous participation in any study of AMG 133.
  37. Blood donation within 3 months, plasma within 2 weeks, or within 6 weeks before check-in.
  38. Unwillingness to follow study requirements or restrictions.
  39. Any other reason, in the investigator's opinion, that makes participation unsuitable.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Group 1 (reference): AMG 133 Concentration A (frozen liquid)

    Participants will receive a single dose of AMG 133 as a SC injection.

    Drug: AMG 133 (frozen liquid)

  • Experimental
    Group 2 (test): AMG 133 Concentration B (liquid)

    Participants will receive a single dose of AMG 133 as a SC injection.

    Drug: AMG 133 (liquid)

  • Experimental
    Group 3 (test): AMG 133 Concentration C (liquid)

    Participants will receive a single dose of AMG 133 as a SC injection.

    Drug: AMG 133 (liquid)

Interventions

  • AMG 133 will be administered as a SC injection.

    Also known as: Maridebart cafraglutide

  • AMG 133 will be administered as a SC injection.

    Also known as: Maridebart cafraglutide

07

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of AMG 133

    Time frame: Up to Day 120

  2. Area Under the Concentration-time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133

    Time frame: Up to Day 120

  3. AUC From Time 0 Extrapolated to Infinity (AUCinf) of AMG 133

    Time frame: Up to Day 120

Secondary outcomes

  1. Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 to Day 120

  2. Number of Participants who Experienced Serious AEs (SAEs)

    Time frame: Screening to Day 120 (up to 148 days)

  3. Number of Participants with Positive Anti-AMG 133 Antibody Formation

    Time frame: Up to Day 120

08

Study locations

4 sites
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Fortrea Clinical Research Unit - Daytona Beach
    Daytona Beach, Florida 32117-5116, United States
  • Fortrea Clinical Research Unit - Dallas
    Dallas, Texas 75247, United States
  • Fortrea Clinical Research Unit Inc. - Madison
    Madison, Wisconsin 53704, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in May 2025, 5 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 5 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartActual
Nov 26, 2024
Primary completionActual
May 22, 2025
CompletionActual
Jun 2, 2025
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07717814
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Nov 26, 2024
Primary completion
May 22, 2025
Completion
Jun 2, 2025
Last update
Jul 21, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion